This could suggest that although the risk of infection with this immunosuppressive treatment appears to be higher, the severity of symptoms in all cases was mild, suggesting that the use of TNF-alpha inhibitors could be a potential treatment for acute respiratory failure caused by SARS-CoV-2 infection (13). This evidence concerns the gene TNF and acute respiratory failure.